1 day Ago By Defense World Staff
Bank of New York Mellon Corp lessened its holdings in Summit Therapeutics Inc. ( NASDAQ:SMMT – Free Report ) by 7.1% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission.
The fund owned 280,365 shares of the company’s stock after selling 21,334 shares during the period. Bank of New York Mellon Corp’s holdings in Summit Therapeutics were worth $2,187,000 at the end of the most recent reporting period. Other hedge funds and other institutional investors have also recently modified their holdings of the company.
Mirae Asset Global Investments Co. Ltd. lifted its stake in Summit Therapeutics by 131.
3% in the first quarter. Mirae Asset Global Investments Co. Ltd.
now owns 40,476 shares of the company’s stock valued at $168,000 after purchasing an additional 22,977 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Summit Therapeutics by 3.
6% during the first quarter. Vanguard Group Inc. now owns 7,269,243 shares of the company’s stock worth $30,095,000 after acquiring an additional 254,261 shares in the last quarter.
Price T Rowe Associates Inc. MD lifted its position in shares of Summit Therapeutics by 18.3% during the first quarter.
Price T Rowe Associates Inc. MD now owns 33,145 shares of the company’s stock worth $138,000 after acquiring an additional 5,139 shares in the last quarter. Virtu Financial LLC lifted its position in shares of Summit Therapeutics by 23.
3% during the first quarter. Virtu Financial LLC now owns 20,372 shares of the company’s stock worth $84,000 after acquiring an additional 3,846 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Summit Therapeutics by 9.
4% during the first quarter. ProShare Advisors LLC now owns 69,995 shares of the company’s stock worth $290,000 after acquiring an additional 6,035 shares in the last quarter. Hedge funds and other institutional investors own 4.
61% of the company’s stock. Summit Therapeutics Stock Down 11.1 % Shares of SMMT opened at $26.
22 on Wednesday. The company has a market capitalization of $18.41 billion, a P/E ratio of -163.
88 and a beta of -0.99. The firm has a 50 day moving average of $13.
13 and a 200 day moving average of $8.05. Summit Therapeutics Inc.
has a twelve month low of $1.64 and a twelve month high of $33.89.
Analyst Ratings Changes Several equities research analysts have issued reports on the company. Citigroup increased their target price on Summit Therapeutics from $13.00 to $19.
00 and gave the stock a “buy” rating in a research report on Monday, September 9th. Stifel Nicolaus increased their target price on Summit Therapeutics from $14.00 to $25.
00 and gave the company a “buy” rating in a research note on Monday, September 9th. Finally, HC Wainwright upped their price target on shares of Summit Therapeutics from $30.00 to $45.
00 and gave the company a “buy” rating in a research report on Monday. View Our Latest Report on SMMT Summit Therapeutics Company Profile ( Free Report ) Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Featured Stories Five stocks we like better than Summit Therapeutics Insider Trading – What You Need to Know Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Investing in Commodities: What Are They? How to Invest in Them Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge Retail Stocks Investing, Explained Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
